Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Specialties
Hematology
Oncology
Musculoskeletal Disorder
Rare Disease
Metabolic Disorder
Cardiovascular Disease
Ophthalmology
Neurology
Infectious Disease
View all Specialties
Technologies
Cell Therapy
MSC
iPSC
Gene Therapy
Genome Editing
Extracellular Vesicles
CAR-T Therapy
TCR Therapy
Tissue-Engineering & Biomaterials
View all Technologies
Topics
Treatment
Immuno-Oncology
Trial Updates
Perspectives
Manufacturing
COVID-19
View all Topics
Conferences
ASH 2022
TCT 2022
Meeting on the Med 2022
ICLE 2022
Advanced Therapies Week 2022
TERMIS 2021
ESGCT 2021
Meeting on the Mesa 2021
Advanced Therapies 2021
View all Conferences
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Tandem Meetings 2023
5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio
• 21 Feb 2023
3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney
• 24 Feb 2023
3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Shah
• 15 Feb 2023
3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah
• 15 Feb 2023
2:47
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt
• 17 Feb 2023
3:48
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik
• 20 Feb 2023
